Study summary
Zanubrutinib gave deeper responses than ibrutinib with fewer heart side effects
36.3%very good partial or complete response with zanubrutinib, vs 25.3% with ibrutinib
What was tested
Zanubrutinib against ibrutinib, two daily BTK inhibitor pills, for symptomatic Waldenström macroglobulinemia.
What they found
- At 44.4 months, deep responses (VGPR or better) were 36.3% with zanubrutinib vs 25.3% with ibrutinib.
- In people with CXCR4 mutations, deep responses were 21.2% vs 10.0%.
- Atrial fibrillation was less common with zanubrutinib (7.9% vs 23.5%), as were hypertension and pneumonia; neutropenia was more common.
What it means
Made zanubrutinib a preferred BTK inhibitor for WM.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.